Table of Contents

According to the World Health Organization, obesity is a chronic, progressive disease that often requires long-term management because it can recur over time.

When treatment stops, appetite can return, food thoughts may come back, and weight regain can happen. In semaglutide trials, participants regained an average of about two-thirds of their previous weight loss within one year of stopping treatment.

That is one reason maintenance dosing is vital. But what is the lowest effective GLP-1 dose that keeps you healthy, stable, and able to afford treatment?

Key Takeaways

  • Alternative GLP-1 dosing means taking a medication on a schedule different from the standard FDA-approved plan.
  • People on forums and discussions often report using maintenance schedules such as every 10 days or every 14 days, usually for cost, side effects, or stopping further weight loss.
  • If you’re considering a different GLP-1 schedule, work with your prescribing physician, especially if you have diabetes, have a history of pancreatitis, or have severe stomach side effects.

How often do you take GLP-1 for weight loss?

For Wegovy injection, treatment starts at 0.25 mg once weekly and increases gradually to the maintenance dose, which is usually 1.7 mg or 2.4 mg once weekly. There’s also a 7.2 mg once-weekly option for adults who tolerate 2.4 mg but need to lose more weight.

For Zepbound, treatment starts at 2.5 mg once weekly, then also increases gradually to the maintenance doses of 5 mg, 10 mg, or 15 mg once weekly. The dose is increased at 2.5 mg increments after every 4 weeks.

These dosing schedules have been carefully tested in clinical trials. Split dosing, microdosing, and other alternative dosing routines are different approaches. Some doctors may recommend them for certain patients, but there’s still limited research on how well they work.

Can you take semaglutide every other week?

A 2025 modeling study found that every-other-week dosing kept roughly 75% of predicted weight loss, while giving a larger dose every two weeks could potentially maintain nearly all of the benefit.

The study modeled semaglutide at maintenance doses of 1.7 mg and 2.4 mg.

For semaglutide 2.4 mg once weekly, the model predicted about 17% steady-state body weight reduction. When the same 2.4 mg dose was taken every 14 days, the model predicted about 12% body weight reduction.

That means the every-other-week schedule kept about 72% of the modeled weight loss while using half as many injections.

For semaglutide 1.7 mg, the model predicted that every-other-week dosing kept about 69% of the weight loss compared with weekly dosing.

The study also modeled a person moving from 1.7 mg weekly to 2.4 mg every other week. In that case, the model estimated about 82% of the original weight loss at about half the injection cost, assuming cost is tied to the number of injections rather than the dose size.

Can you take tirzepatide every other week?

The model predicted steady-state body weight reductions of about 17%, 21%, and 23% for tirzepatide doses of 5 mg, 10 mg, and 15 mg taken once weekly. When those same doses were taken every two weeks, the model predicted weight reductions of about 12%, 16%, and 18%.

In short, people were predicted to keep roughly 75% of the weight loss when switching from weekly dosing to every-other-week dosing.

The model also suggested that some higher-dose, less frequent tirzepatide schedules might produce results close to lower-dose weekly schedules. For example, 5 mg weekly was modeled as roughly similar to 10 mg every 14 days. The paper also noted that 10 mg weekly looked roughly similar to 15 mg every 10 days in the model.

Is dosing GLP-1 every other week still effective?

Taking your GLP-1 dose every other week may still be effective, but mainly as a maintenance approach after reaching your goal weight. If you are still early in treatment or actively trying to lose weight, dosing less often may reduce the medication’s effect and make it harder to reach your goal.

A case series found that some adults who had already lost weight on weekly semaglutide or tirzepatide were able to maintain their results after switching to reduced-frequency dosing, usually every other week. In fact, their average weight dropped a little more during maintenance, from 74.1 kg to 72.4 kg, about 1.7 kg or 3.7 lb of additional average weight loss.

These patients had already reached a weight plateau before changing their schedule. Over an average of about 36 weeks, they maintained their weight loss, preserved metabolic improvements, and had stable skeletal muscle mass.

Do GLP-1s wear off by the end of the week?

Many injectable GLP-1 medications are designed to last for days. After a shot, the drug level rises, then slowly falls. If the next shot comes later than usual, there may still be some medication in the body, just less than there would be on a weekly schedule.

Semaglutide has a longer half-life of about 1 week and reaches steady levels after roughly 4 to 5 weeks of weekly dosing. Tirzepatide has a half-life of about 5 days, which also supports once-weekly dosing.

Weekly vs Every-Other-Week GLP-1 Chart

This visual shows how GLP-1 medication levels may rise and fall when the same dose is taken once weekly compared with every other week. It is a simplified educational model based on drug half-life.

Important: This chart is for education only. It is not a dosing calculator and should not be used to change your medication schedule. Semaglutide and tirzepatide are approved with specific dosing instructions. Always follow your prescriber’s guidance.
Standard schedule 2.4 mg every week
Maintenance example 2.4 mg every other week
Once weekly
Every other week

GLP-1 maintenance dosing after weight loss

Here are some of the personal experiences shared on Reddit threads about Ozempic, Wegovy, Mounjaro, and Zepbound maintenance.

These stories line up with the study’s general idea that some people may maintain benefits with less medication. But they also show that there is no one-size plan. Some people do well with spacing. Some need weekly treatment. Some need dose changes over time.

  • Some users report taking shots every 10 days or every 14 days for maintenance. For example, one Wegovy user said they moved to 1.7 mg every 14 days after first trying 10 to 12 days, with more hunger but a manageable appetite.
  • Cost comes up often. In one Wegovy discussion, a commenter noted that dosing every 14 days can make treatment much cheaper for people paying out of pocket.

Comment
byu/Auraluka from discussion
inWegovyWeightLoss

  • Some tirzepatide users describe maintenance schedules such as 7.5 mg every 10 days or 5 mg every 10 days. One Mounjaro user said 7.5 mg every 10 days was working for maintenance, while another said 5 mg every 10 days worked for several months before they needed to adjust.

Comment
byu/AnyMathGirl from discussion
inMounjaro

  • Some people report lower doses rather than longer spacing. One Ozempic user said they lost 105 pounds and maintained on 0.25 mg after previously using 1 mg.

Comment
byu/jasminee2020 from discussion
inOzempic

Benefits of alternative GLP-1 dosing

  • Lower cost. If someone uses fewer injections per month and pays per pen, vial, or fill, the monthly expense may drop.
  • Fewer side effects. Many people feel nausea, fatigue, reflux, or appetite loss more strongly soon after a dose. Fewer doses could reduce side effects for some people, although this remains uncertain.
  • Improve patient adherence. In a study of more than 4,000 people without diabetes who started GLP-1 therapy for obesity, only about 1 in 3 stayed on treatment for one year, and only 27% took it as intended. If a plan is more affordable and easier to tolerate, a patient may be more likely to continue treatment.

Possible risks and unknowns of alternative GLP-1 dosing

  • The biggest risk is that alternative dosing has not been proven in large clinical trials.
  • Less frequent dosing may create more up-and-down drug levels. The study earlier noted that switching from weekly to every-other-week dosing increased the peak-to-trough difference by 34% for semaglutide and 9% for tirzepatide. Higher peaks and lower troughs could affect side effects or appetite control.
  • Pens and vials are not always designed for custom schedules or custom doses. Splitting doses, using compounded products, or changing injection amounts can introduce dosing errors.

Who should be extra careful?

  • People with type 2 diabetes should involve their prescriber because glucose control can change.
  • People using insulin or sulfonylureas need medical supervision due to the risk of low blood sugar.
  • People with severe nausea, vomiting, dehydration, reflux, constipation, or abdominal pain should not assume spacing doses will solve the problem.
  • People with a history of pancreatitis, gallbladder disease, gastroparesis, or kidney problems need individualized care.
  • People using compounded products should be careful about concentration, units, source, and sterility.

How to talk to your doctor about GLP-1 maintenance dose

If you are interested in alternative dosing, bring it up directly. You can ask questions such as these.

    • Am I a good candidate for a lower maintenance dose?
    • Would spacing my dose be safer than stopping completely?
    • How should I track weight, appetite, side effects, and blood sugar?
    • What symptoms should make me call you right away?
    • If my weight starts to rise, when should we adjust the plan?
    • Does my insurance or pharmacy setup make one option more affordable?

It may help to track your weight trend, hunger level, protein intake, activity, side effects, and medication dates for a few weeks.

Bottom line

GLP-1 dosing may eventually become more personalized than the standard once-weekly schedule, especially for maintenance. But for now, alternative regimens should be treated as a doctor-guided strategy, and not a do-it-yourself hack.

Alternative dosing may be more relevant after a person has already reached a stable dose, knows how they respond, and is discussing long-term maintenance with a clinician.

For new patients, ask how long treatment may last, what maintenance might look like, what happens if insurance stops covering it, and what lifestyle habits will support results.

Frequently Asked Questions

GLP-1 medication for weight loss is intended for long-term use. You can continue taking your GLP-1 dose if it is still working, tolerated well, and medically appropriate. Obesity is often treated as a chronic condition, and research shows that weight regain can happen after stopping. In a semaglutide study, participants regained much of the weight they had lost within a year after stopping treatment.
Not necessarily, but some people may need long-term treatment to maintain their results. Medical professionals recommend continuing weight-loss medication when it is effective and safe, and stopping or changing treatment if it does not work well or causes problems. Your provider may adjust your dose, switch medications, or discuss a maintenance plan based on your weight trend, side effects, health conditions, and goals.
You should not split your semaglutide dose into twice-weekly injections unless your prescriber specifically tells you to. Splitting doses may increase the risk of dosing mistakes, especially with compounded products or multi-dose vials. Talk to your clinician before changing your dose timing.
Some people report doing this for maintenance, and a 2025 modeling study suggests every-other-week semaglutide may preserve much of the weight loss effect. However, the standard labeled schedule is once weekly for injectable semaglutide. Talk to your prescriber before changing timing.
Some patients report 10-day or 14-day maintenance schedules online. The 2025 study modeled less frequent tirzepatide dosing and found that some schedules may maintain much of the predicted weight loss. Still, Zepbound and Mounjaro are labeled for once-weekly dosing, so changes should be supervised.
It is not fully known. The study was based on mathematical modeling, not a clinical trial. Less frequent dosing may reduce side effects for some people, but it may also create more drug-level swings. People with diabetes need extra caution.
The most common reasons are cost, maintenance after reaching goal weight, side effects, continued weight loss beyond goal, medication shortages, or insurance changes.
Some people may do better with a lower weekly dose. Others may do better with a longer interval. The right choice depends on weight trend, appetite, side effects, blood sugar, medication access, and medical history.
Many people regain weight after stopping. In a STEP 1 semaglutide extension study, participants regained about two-thirds of their prior weight loss within one year after withdrawal. This is one reason many clinicians discuss long-term maintenance rather than sudden stopping.

Sources

Cengiz A, Wu CC, Lawley SD. Alternative dosing regimens of GLP-1 receptor agonists may reduce costs and maintain weight loss efficacy. Diabetes Obes Metab. 2025 Apr;27(4):2251-2258. doi: 10.1111/dom.16229. Epub 2025 Feb 14. PMID: 39950222; PMCID: PMC11885104.

Wilding JPH, Batterham RL, Davies M, Van Gaal LF, Kandler K, Konakli K, Lingvay I, McGowan BM, Oral TK, Rosenstock J, Wadden TA, Wharton S, Yokote K, Kushner RF; STEP 1 Study Group. Weight regain and cardiometabolic effects after withdrawal of semaglutide: The STEP 1 trial extension. Diabetes Obes Metab. 2022 Aug;24(8):1553-1564. doi: 10.1111/dom.14725. Epub 2022 May 19. PMID: 35441470; PMCID: PMC9542252.

Gleason, P. P., Urick, B. Y., Marshall, L. Z., Friedlander, N., Qiu, Y., & Leslie, R. S. (2024). Real-world persistence and adherence to glucagon-like peptide-1 receptor agonists among obese commercially insured adults without diabetes. Journal of Managed Care & Specialty Pharmacy, 30(8), 860–867. https://doi.org/10.18553/jmcp.2024.23332

Wong, M., Wu, A., Garhe, P. K., & Biermann, M. (2026). Reduced?Frequency GLP1 therapy maintains weight, body composition, and metabolic syndrome improvements: a case series. Obesity, 34(S1), 112–120. https://doi.org/10.1002/oby.70137